These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 20557351)

  • 1. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
    Hafner C; Landthaler M; Vogt T
    Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
    Ismail SI; Mahmoud IS; Msallam MM; Sughayer MA
    Leuk Res; 2010 Jun; 34(6):824-6. PubMed ID: 20022634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
    Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Ellis IO; Green AR
    Breast Cancer Res Treat; 2011 Jun; 127(2):407-16. PubMed ID: 20617378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
    Fenic I; Steger K; Gruber C; Arens C; Woenckhaus J
    Oncol Rep; 2007 Jul; 18(1):253-9. PubMed ID: 17549376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
    Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
    Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
    Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
    Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RUNX3 in skin cancers.
    Lee JH; Pyon JK; Kim DW; Lee SH; Nam HS; Kang SG; Kim CH; Lee YJ; Chun JS; Cho MK
    Clin Exp Dermatol; 2011 Oct; 36(7):769-74. PubMed ID: 21623876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
    Baohua Y; Xiaoyan Z; Tiecheng Z; Tao Q; Daren S
    Diagn Mol Pathol; 2008 Sep; 17(3):159-65. PubMed ID: 18382359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
    Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H
    Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
    Ekizoglu S; Dogan S; Ulker D; Seven D; Gozen ED; Karaman E; Buyru N
    Clin Otolaryngol; 2015 Dec; 40(6):622-8. PubMed ID: 25850957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKT1(E17K) in human solid tumours.
    Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
    Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of COX-2 activity and CRP levels in patients with non-melanoma skin cancer. -765G>C PTGS2 polymorphism and NMSC risk.
    Cocoş R; Schipor S; Nicolae I; Thomescu C; Raicu F
    Arch Dermatol Res; 2012 Jul; 304(5):335-42. PubMed ID: 22159575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical galectin-3 expression in non-melanoma skin cancers.
    Kapucuoglu N; Basak PY; Bircan S; Sert S; Akkaya VB
    Pathol Res Pract; 2009; 205(2):97-103. PubMed ID: 18951731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.